Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $42.34.
A number of equities research analysts have issued reports on the stock. BTIG Research cut their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research note on Friday, November 29th. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Finally, Ascendiant Capital Markets dropped their price objective on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.
Get Our Latest Research Report on OTLK
Outlook Therapeutics Stock Performance
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently made changes to their positions in the company. AQR Capital Management LLC bought a new position in Outlook Therapeutics in the second quarter worth $75,000. Christensen King & Associates Investment Services Inc. purchased a new stake in shares of Outlook Therapeutics in the 3rd quarter worth about $55,000. Barclays PLC increased its stake in shares of Outlook Therapeutics by 677.4% in the 3rd quarter. Barclays PLC now owns 20,943 shares of the company’s stock worth $111,000 after acquiring an additional 18,249 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Outlook Therapeutics by 55.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 51,459 shares of the company’s stock valued at $275,000 after acquiring an additional 18,287 shares during the period. Finally, State Street Corp boosted its stake in Outlook Therapeutics by 10.0% during the third quarter. State Street Corp now owns 232,542 shares of the company’s stock worth $1,242,000 after acquiring an additional 21,201 shares in the last quarter. Hedge funds and other institutional investors own 11.20% of the company’s stock.
About Outlook Therapeutics
Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Featured Articles
- Five stocks we like better than Outlook Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- How to Invest in Blue Chip Stocks
- 2 Drone Stocks Surging from Increased Media Attention
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.